Biopharma firm Disc Medicine's Q3 net loss widens

Disc Medicine

06/11/2025 13:40

Overview

Disc Medicine Q3 net loss and EPS miss analyst expectations

Company submitted NDA for bitopertin, received priority review voucher

Disc Medicine's cash position extends runway into 2029 after public offering

Outlook

Disc Medicine expects potential US approval of bitopertin in late 2025 or early 2026

Result Drivers

R&D expenses were $50.3 million for the three months ended September 30, 2025, as compared to $24.7 million for the three months ended September 30, 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
Miss
-$62.32 mln
-$52.10 mln (8 Analysts)
Q3 Basic EPS
Miss
-$1.77
-$1.51 (11 Analysts)
Q3 Operating Income
Miss
-$67.70 mln
-$55.50 mln (8 Analysts)
Q3 Operating Expenses
$67.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Disc Medicine Inc is $115.00, about 23.2% above its November 5 closing price of $88.31

Press Release: ID:nGNX1dfLSD

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)